CNXU Conexeu Sciences Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 2066836 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets18.2%
Debt / equity0.00x
Current ratio5.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-07-31 | 2026Q22026-04-30 | 2025Q32025-07-31 | 2025Q22025-04-30 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $270,412 | $66,605 | $134,662 | $42,465 |
| SG&A expense | $34,647 | $16,867 | $1,282 | $5,720 |
| Operating income | -$7.69M | -$2.38M | -$1.30M | -$456,981 |
| Interest expense | $0 | $0 | -$43 | $1,383 |
| Pretax income | -$7.73M | -$2.30M | -$1.30M | -$458,050 |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$7.73M | -$2.30M | -$1.30M | -$458,050 |
| EBITDA | -$7.68M | -$2.37M | -$1.29M | -$453,580 |
| EPS (basic) | -0.29 | -0.11 | -0.09 | -0.05 |
| EPS (diluted) | -0.29 | -0.11 | -0.09 | -0.05 |
| Weighted avg. shares (diluted) | 26.97M | 20.57M | 14.10M | 9.51M |
| Balance sheet | ||||
| Cash & equivalents | $1.97M | $6.85M | $833,128 | $79,436 |
| Current assets | $6.76M | $7.91M | — | — |
| PP&E, net | $74,318 | $38,400 | — | — |
| Intangibles | $163,996 | $163,949 | — | — |
| Total assets | $7.16M | $8.20M | — | — |
| Current liabilities | $1.27M | — | — | — |
| Total liabilities | $1.31M | $1.00M | — | — |
| Shareholders' equity | $5.85M | $7.20M | $1.65M | $176,745 |
| Shares outstanding | 27.40M | 20.92M | — | — |
| Cash flow statement | ||||
| Operating cash flow | -$6.76M | — | -$573,805 | — |
| Capital expenditure | $41,400 | — | $400 | — |
| Free cash flow | -$6.80M | — | -$574,205 | — |
| Investing cash flow | -$41,400 | — | -$40,786 | — |
| Financing cash flow | $1.70M | — | $1.37M | — |
| Depreciation & amortization | $5,435 | $11,422 | $6,640 | $3,401 |
| Stock-based compensation | $1.04M | — | -$64,311 | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.